How to return Neupro®
Neupro® (Rotigotine Transdermal System) patches were recalled in the United States on May 1, 2008 and are no longer available. If you have Neupro samples or boxes of Neupro that you would like to return to UCB, the makers of Neupro, please click on one of the links below for instructions.
Neupro® is indicated for the treatment of the signs and symptoms of early-stage idiopathic (meaning the cause is not known) Parkinson's disease. Some patients treated with Neupro reported falling asleep without any warning signs while engaged in activities of daily living such as driving, which sometimes resulted in accidents. Hallucinations such as seeing, hearing, or sensing things that were not real were reported in 2.0% of patients treated with Neupro compared to 0.7% of patients on placebo.
The most commonly reported side effects in clinical trials were nausea, application site reactions, somnolence (sleepiness), dizziness, headache, vomiting, and insomnia.
Neupro should be used with caution in patients, especially those at risk for heart disease, because of the potential for symptomatic hypotension (low blood pressure), syncope (feeling faint), elevated heart rate, elevated blood pressure, fluid retention, and/or weight gain. All Parkinson's disease patients are at a higher risk for melanoma (a type of skin cancer) and should be monitored regularly. Some patients who received Neupro experienced a decrease in blood hemoglobin. It is not known whether this change is readily reversible after stopping Neupro.
© Copyright 2008 UCB, Inc.
Neupro and Parkinson’s Patch are trademarks of UCB S.A. or its affiliates
